Last updated Nov 10, 2026
A 4-year-old boy with autism and developmental delays has a long face and prominent ears. His maternal grandfather has tremor and balance problems.
X-linked; CGG repeat expansion in the 5' UTR of FMR1 (FMRP, an RNA-binding protein); a full mutation silences the gene, while a premutation is thought to act through toxic mRNA
- Normal: about 5-44 repeats
- Intermediate (gray zone): 45-54 (does not cause disease; about 14% are unstable and may expand into the premutation range when the mother transmits them; not known to expand to a full mutation)
- Premutation: 55-200, unmethylated (risk for FXTAS, FXPOI)
- Full mutation: >200 (hypermethylation of the promoter → gene silencing)
- Exhibits genetic anticipation through maternal transmission (premutation → full mutation); a father's premutation does not become a full mutation
FMRP binds a subset of mRNAs in the cytoplasm of neurons and other cells and regulates translation of proteins that maintain synapses, so it shapes synaptic plasticity. Without it, signaling through the metabotropic glutamate receptor (mGluR) is disrupted.
- Full mutation (>200 CGG): the expanded repeat and promoter are hypermethylated, transcription stops, and FMRP is lost. This loss of function is fragile X syndrome. More than 99% of cases are this expansion; deletions and single-nucleotide variants cause the rest.
- Premutation (55-200 CGG): the gene is not methylated and FMR1 mRNA rises. FXTAS and FXPOI are thought to come from toxicity of that excess mRNA (a gain of function), not from loss of FMRP. Longer premutations give earlier and more severe FXTAS; FXPOI risk peaks at 80-99 repeats.
Mosaicism explains much of the range. Males with repeat-size or methylation mosaicism, or an unmethylated full mutation, still make some FMRP and can be higher functioning. In females, severity is believed to follow the share of brain cells whose active X carries the full mutation. AGG interruptions stabilize the repeat, so AGG testing refines the expansion risk of a maternal premutation under 100 repeats.
Males:
- Intellectual disability (moderate)
- Long face, prominent ears, prominent jaw
- Macroorchidism (postpubertal)
- Behavioral: autism, ADHD, anxiety, hand-flapping
Premutation carriers (55-200 repeats):
- Females: Fragile X-associated primary ovarian insufficiency (FXPOI)
- Males (and some females): Fragile X-associated tremor/ataxia syndrome (FXTAS) - late onset
A late-onset neurodegenerative disorder of premutation carriers (55-200 CGG repeats), distinct from Fragile X syndrome (full mutation), which is caused by loss of FMRP. FXTAS is instead an RNA gain-of-function toxicity from elevated FMR1 mRNA containing the expanded CGG tract, which sequesters RNA-binding proteins and produces ubiquitin-positive intranuclear inclusions.
Who develops FXTAS:
- Predominantly males (~40% of male carriers >50 yrs); penetrance rises sharply with age
- A minority of female carriers (~16-20%); milder due to X-inactivation
- Risk increases with longer premutation size (within the 55-200 window)
Clinical features:
- Progressive intention tremor and cerebellar ataxia (gait and limb)
- Parkinsonism, autonomic dysfunction (impotence, orthostasis), peripheral neuropathy
- Cognitive decline → executive dysfunction, eventual frontal-subcortical dementia
- Mood symptoms (anxiety, depression, irritability) often precede motor signs
Imaging:
- MCP sign: hyperintensity of the middle cerebellar peduncles on T2/FLAIR (highly characteristic)
- Generalized cerebral and cerebellar atrophy, splenium of corpus callosum hyperintensity
Counseling implications:
- Older male relatives of a Fragile X proband presenting with "atypical Parkinson disease," "cerebellar tremor," or "Lewy body dementia" should be tested for an FMR1 premutation
- A maternal grandfather with tremor/ataxia is a classic family-history clue
FMR1 CGG repeat sizing and DNA methylation analysis (how each method works: Repeat expansion testing)
| Test | Method | Purpose |
|---|---|---|
| Repeat sizing | PCR + capillary electrophoresis | Normal (≤44), intermediate (45-54), and premutation (55-200) |
| Repeat sizing | Southern blot | Full mutation (>200); detects mosaicism |
| Methylation analysis | Southern blot (methylation-sensitive restriction enzymes) | Confirms promoter hypermethylation |
| Methylation analysis | Methylation-sensitive PCR | Alternative methylation detection |
- The most severe symptoms happen in the presence of a full mutation with complete promoter methylation. Patients with a full mutation but "incomplete" DNA methylation have milder symptoms.
- No cure; supportive care with early developmental, behavioral, speech, and educational intervention
- Treat comorbid ADHD, anxiety, aggression, and autism features pharmacologically and behaviorally as indicated
- Surveillance for associated issues: recurrent otitis media, strabismus, seizures, connective-tissue features (joint laxity, mitral valve prolapse)
- Counsel female premutation carriers about FXPOI (fertility, early menopause) and carriers about FXTAS risk; offer cascade testing and reproductive options including prenatal/preimplantation testing
Fragile X is all about 4's and 5's:
- 45-54 = intermediate range
- 55 or more = premutation or full mutation
- 5' UTR location
- Menopause before 40 = FXPOI
This table summarizes the major nucleotide repeat disorders including Fragile X, Friedreich ataxia, myotonic dystrophy, Huntington disease, and spinocerebellar ataxias.

Fragile X premutation carriers are at risk for primary ovarian insufficiency (FXPOI), one of several genetic causes of early menopause remembered with "Gonads Turn Off Before Forty."
